Latest Cytrx Corp (CYTR) Headlines
CytRx Shares Up 51.7% Since SmarTrend's Buy Recommendation (CYTR)
Comtex SmarTrend(R) - Wed Mar 05, 4:57PM CST
SmarTrend identified an Uptrend for CytRx (NASDAQ:CYTR) on December 11th, 2013 at $3.92. In approximately 3 months, CytRx has returned 51.72% as of today's recent price of $5.94.
CytRx Reports 2013 Financial Results
Business Wire - Wed Mar 05, 5:00AM CST
CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today reported financial results for the 12 months ended December 31, 2013, and also provided an overview of recent accomplishments and upcoming milestones for its clinical development programs.
Research Report: AIDS - Related Kaposi's Sarcoma - Pipeline Review, H1 2014
M2 - Mon Feb 24, 3:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/k5svvq/aids_related) has announced the addition of the "AIDS - Related Kaposi's Sarcoma - Pipeline Review, H1 2014" report to their offering. 'AIDS - Related Kaposi's Sarcoma - Pipeline Review, H1 2014', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for AIDS - Related Kaposi's Sarcoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for AIDS - Related Kaposi's Sarcoma. Scope - A snapshot of the global therapeutic scenario for AIDS - Related Kaposi's Sarcoma. - A review of the AIDS - Related Kaposi's Sarcoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the AIDS - Related Kaposi's Sarcoma pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction AIDS - Related Kaposi's Sarcoma Overview Therapeutics Development Pipeline Products for AIDS - Related Kaposi's Sarcoma - Overview Pipeline Products for AIDS - Related Kaposi's Sarcoma - Comparative Analysis AIDS - Related Kaposi's Sarcoma - Therapeutics under Development by Companies AIDS - Related Kaposi's Sarcoma - Pipeline Products Glance Clinical Stage Products Early Stage Products AIDS - Related Kaposi's Sarcoma - Products under Development by Companies AIDS - Related Kaposi's Sarcoma - Companies Involved in Therapeutics Development AIDS - Related Kaposi's Sarcoma - Therapeutics Assessment Drug Profiles aldoxorubicin - Drug Profile paclitaxel nanosomal - Drug Profile CS-TATI-1 - Drug Profile interferon alfa-2a biosimilar - Drug Profile interferon alfa-2b - Drug Profile interferon alfa-2a - Drug Profile R&D Progress Featured News & Press Releases Appendix Companies Mentioned Aphios Corporation CytRx Corporation Cannabis Science, Inc. Xiamen Amoytop Biotech Co., Ltd. Biogenomics For more information visit http://www.researchandmarkets.com/research/k5...ds_related About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CytRx Corporation (CYTR) Showing Signs Of A Dead Cat Bounce Today
at The Street - Thu Feb 13, 9:28AM CST
Trade-Ideas LLC identified CytRx Corporation (CYTR) as a "dead cat bounce" (down big yesterday but up big today) candidate
Catasys Announces Transition to a New Board of Directors
PR Newswire - Thu Feb 13, 8:00AM CST
Catasys, Inc. (OTC BB: CATS), provider of proprietary health management services to health insurers and employers, today announced the transition to a new Board of Directors.
Hepatic (Liver) Metastasis - Pipeline Review, H2 2013 Research Report
M2 - Thu Feb 13, 2:58AM CST
Research and Markets (http://www.researchandmarkets.com/research/v9wq5t/hepatic_liver) has announced the addition of the "Hepatic (Liver) Metastasis - Pipeline Review, H2 2013" report to their offering. 'Hepatic (Liver) Metastasis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hepatic (Liver) Metastasis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hepatic (Liver) Metastasis. Scope - A snapshot of the global therapeutic scenario for Hepatic (Liver) Metastasis. - A review of the Hepatic (Liver) Metastasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Hepatic (Liver) Metastasis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Hepatic (Liver) Metastasis Overview Therapeutics Development Clinical Stage Products Early Stage Products Drug Profiles icosapent - Drug Profile Product Description Mechanism of Action R&D Progress FANG Vaccine - Drug Profile Product Description Mechanism of Action R&D Progress 177Lu-DOTA-TATE - Drug Profile Product Description Mechanism of Action R&D Progress pasireotide - Drug Profile Product Description Mechanism of Action R&D Progress entolimod - Drug Profile Product Description Mechanism of Action R&D Progress Curcumin C3-Complex [fluorouracil] [oxaliplatin] [leucovorin calcium] - Drug Profile Product Description Mechanism of Action R&D Progress mepacrine - Drug Profile Product Description Mechanism of Action R&D Progress disulfiram [copper gluconate] - Drug Profile Product Description Mechanism of Action R&D Progress Salmonella typhimurium - Drug Profile Product Description Mechanism of Action R&D Progress Anti-CEA Designer T Cells - Drug Profile Product Description Mechanism of Action R&D Progress Antibody Against FERM Domain-Containing Protein 4A - Drug Profile Product Description Mechanism of Action R&D Progress Hepatic (Liver) Metastasis - Recent Pipeline Updates Hepatic (Liver) Metastasis - Dormant Projects Hepatic (Liver) Metastasis - Product Development Milestones Featured News & Press Releases Companies Mentioned Novartis AG Cleveland BioLabs, Inc. CytRx Corporation S.L.A. Pharma AG Incuron, LLC Gradalis Inc. TARGETOME For more information visit http://www.researchandmarkets.com/research/v9...atic_liver About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Nasdaq stocks posting largest percentage decreases
AP - Wed Feb 12, 5:04PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Galena Biopharma Pays For Stock-Touting Campaign While Insiders Cash Out Millions
at The Street - Wed Feb 12, 4:54PM CST
Seeking Alpha removes articles after finding single author used multiple aliases to promote Galena.
66.0% Return Seen to Date on SmarTrend CytRx Call (CYTR)
Comtex SmarTrend(R) - Wed Feb 12, 9:13AM CST
SmarTrend identified an Uptrend for CytRx (NASDAQ:CYTR) on December 11th, 2013 at $3.92. In approximately 2 months, CytRx has returned 66.03% as of today's recent price of $6.50.
CytRx Corporation completes USD86.0m public offering, including full exercise of underwriters' option
M2 - Thu Feb 06, 4:27AM CST
Biopharmaceutical company CytRx Corporation (NasdaqCM:CYTR) said on Wednesday that it has closed a public offering of its common stock at a price of USD6.50 per share.
CytRx Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Business Wire - Wed Feb 05, 11:01AM CST
CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced the closing of its previously announced underwritten public offering. The gross proceeds to CytRx from its sale of 13,225,000 shares of common stock at a price to the public of $6.50 per share, which include the proceeds from the exercise of the underwriters' option to purchase an additional 1,725,000 shares, were approximately $86.0 million, prior to deducting underwriting discounts and commissions and other offering expenses payable by CytRx.
Shares of CYTR Up 67.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Feb 04, 4:45PM CST
SmarTrend identified an Uptrend for CytRx (NASDAQ:CYTR) on December 11th, 2013 at $3.92. In approximately 2 months, CytRx has returned 67.82% as of today's recent price of $6.57.
Trade-Ideas: CytRx Corporation (CYTR) Is Today's "Dead Cat Bounce" Stock
at The Street - Mon Feb 03, 8:47AM CST
Trade-Ideas LLC identified CytRx Corporation (CYTR) as a "dead cat bounce" (down big yesterday but up big today) candidate
What to Watch at Merck, CytRx, and Mylan This Morning
Leo Sun, The Motley Fool - Motley Fool - Mon Feb 03, 8:16AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Good morning, fellow Foolish investors! Let's take a closer...
CytRx to Present at the 16th Annual BIO CEO & Investor Conference on February 10, 2014, in New York City
Business Wire - Mon Feb 03, 5:30AM CST
CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that President and CEO Steven A. Kriegsman and Vice President of Business Development David Haen will present at the 16th Annual BIO CEO & Investor Conference on Monday, February 10, 2014, at 2:30 p.m. Eastern time (11:30 a.m. Pacific time). The conference is being held February 10-11 at the Waldorf Astoria Hotel in New York City.
Sorrento Therapeutics Welcomes Daniel Levitt as a Director to its Board
PR Newswire - Mon Feb 03, 5:00AM CST
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento) a late-stage clinical oncology company developing new treatments for cancer and associated pain, today announced the addition of Clinical Oncologist Daniel Levitt, M.D., Ph.D., as a member to its Board of Directors. He currently serves as Executive Vice President and Chief Medical Officer of CytRx Corporation.
CytRx Shares Up 51.7% Since SmarTrend's Buy Recommendation (CYTR)
Comtex SmarTrend(R) - Wed Mar 05, 4:57PM CST
SmarTrend identified an Uptrend for CytRx (NASDAQ:CYTR) on December 11th, 2013 at $3.92. In approximately 3 months, CytRx has returned 51.72% as of today's recent price of $5.94.
CytRx Reports 2013 Financial Results
Business Wire - Wed Mar 05, 5:00AM CST
CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today reported financial results for the 12 months ended December 31, 2013, and also provided an overview of recent accomplishments and upcoming milestones for its clinical development programs.
Research Report: AIDS - Related Kaposi's Sarcoma - Pipeline Review, H1 2014
M2 - Mon Feb 24, 3:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/k5svvq/aids_related) has announced the addition of the "AIDS - Related Kaposi's Sarcoma - Pipeline Review, H1 2014" report to their offering. 'AIDS - Related Kaposi's Sarcoma - Pipeline Review, H1 2014', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for AIDS - Related Kaposi's Sarcoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for AIDS - Related Kaposi's Sarcoma. Scope - A snapshot of the global therapeutic scenario for AIDS - Related Kaposi's Sarcoma. - A review of the AIDS - Related Kaposi's Sarcoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the AIDS - Related Kaposi's Sarcoma pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction AIDS - Related Kaposi's Sarcoma Overview Therapeutics Development Pipeline Products for AIDS - Related Kaposi's Sarcoma - Overview Pipeline Products for AIDS - Related Kaposi's Sarcoma - Comparative Analysis AIDS - Related Kaposi's Sarcoma - Therapeutics under Development by Companies AIDS - Related Kaposi's Sarcoma - Pipeline Products Glance Clinical Stage Products Early Stage Products AIDS - Related Kaposi's Sarcoma - Products under Development by Companies AIDS - Related Kaposi's Sarcoma - Companies Involved in Therapeutics Development AIDS - Related Kaposi's Sarcoma - Therapeutics Assessment Drug Profiles aldoxorubicin - Drug Profile paclitaxel nanosomal - Drug Profile CS-TATI-1 - Drug Profile interferon alfa-2a biosimilar - Drug Profile interferon alfa-2b - Drug Profile interferon alfa-2a - Drug Profile R&D Progress Featured News & Press Releases Appendix Companies Mentioned Aphios Corporation CytRx Corporation Cannabis Science, Inc. Xiamen Amoytop Biotech Co., Ltd. Biogenomics For more information visit http://www.researchandmarkets.com/research/k5...ds_related About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CytRx Corporation (CYTR) Showing Signs Of A Dead Cat Bounce Today
at The Street - Thu Feb 13, 9:28AM CST
Trade-Ideas LLC identified CytRx Corporation (CYTR) as a "dead cat bounce" (down big yesterday but up big today) candidate
Catasys Announces Transition to a New Board of Directors
PR Newswire - Thu Feb 13, 8:00AM CST
Catasys, Inc. (OTC BB: CATS), provider of proprietary health management services to health insurers and employers, today announced the transition to a new Board of Directors.
Hepatic (Liver) Metastasis - Pipeline Review, H2 2013 Research Report
M2 - Thu Feb 13, 2:58AM CST
Research and Markets (http://www.researchandmarkets.com/research/v9wq5t/hepatic_liver) has announced the addition of the "Hepatic (Liver) Metastasis - Pipeline Review, H2 2013" report to their offering. 'Hepatic (Liver) Metastasis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hepatic (Liver) Metastasis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hepatic (Liver) Metastasis. Scope - A snapshot of the global therapeutic scenario for Hepatic (Liver) Metastasis. - A review of the Hepatic (Liver) Metastasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Hepatic (Liver) Metastasis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Hepatic (Liver) Metastasis Overview Therapeutics Development Clinical Stage Products Early Stage Products Drug Profiles icosapent - Drug Profile Product Description Mechanism of Action R&D Progress FANG Vaccine - Drug Profile Product Description Mechanism of Action R&D Progress 177Lu-DOTA-TATE - Drug Profile Product Description Mechanism of Action R&D Progress pasireotide - Drug Profile Product Description Mechanism of Action R&D Progress entolimod - Drug Profile Product Description Mechanism of Action R&D Progress Curcumin C3-Complex [fluorouracil] [oxaliplatin] [leucovorin calcium] - Drug Profile Product Description Mechanism of Action R&D Progress mepacrine - Drug Profile Product Description Mechanism of Action R&D Progress disulfiram [copper gluconate] - Drug Profile Product Description Mechanism of Action R&D Progress Salmonella typhimurium - Drug Profile Product Description Mechanism of Action R&D Progress Anti-CEA Designer T Cells - Drug Profile Product Description Mechanism of Action R&D Progress Antibody Against FERM Domain-Containing Protein 4A - Drug Profile Product Description Mechanism of Action R&D Progress Hepatic (Liver) Metastasis - Recent Pipeline Updates Hepatic (Liver) Metastasis - Dormant Projects Hepatic (Liver) Metastasis - Product Development Milestones Featured News & Press Releases Companies Mentioned Novartis AG Cleveland BioLabs, Inc. CytRx Corporation S.L.A. Pharma AG Incuron, LLC Gradalis Inc. TARGETOME For more information visit http://www.researchandmarkets.com/research/v9...atic_liver About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Nasdaq stocks posting largest percentage decreases
AP - Wed Feb 12, 5:04PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Galena Biopharma Pays For Stock-Touting Campaign While Insiders Cash Out Millions
at The Street - Wed Feb 12, 4:54PM CST
Seeking Alpha removes articles after finding single author used multiple aliases to promote Galena.
66.0% Return Seen to Date on SmarTrend CytRx Call (CYTR)
Comtex SmarTrend(R) - Wed Feb 12, 9:13AM CST
SmarTrend identified an Uptrend for CytRx (NASDAQ:CYTR) on December 11th, 2013 at $3.92. In approximately 2 months, CytRx has returned 66.03% as of today's recent price of $6.50.
CytRx Corporation completes USD86.0m public offering, including full exercise of underwriters' option
M2 - Thu Feb 06, 4:27AM CST
Biopharmaceutical company CytRx Corporation (NasdaqCM:CYTR) said on Wednesday that it has closed a public offering of its common stock at a price of USD6.50 per share.
CytRx Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Business Wire - Wed Feb 05, 11:01AM CST
CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced the closing of its previously announced underwritten public offering. The gross proceeds to CytRx from its sale of 13,225,000 shares of common stock at a price to the public of $6.50 per share, which include the proceeds from the exercise of the underwriters' option to purchase an additional 1,725,000 shares, were approximately $86.0 million, prior to deducting underwriting discounts and commissions and other offering expenses payable by CytRx.
Shares of CYTR Up 67.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Feb 04, 4:45PM CST
SmarTrend identified an Uptrend for CytRx (NASDAQ:CYTR) on December 11th, 2013 at $3.92. In approximately 2 months, CytRx has returned 67.82% as of today's recent price of $6.57.
Trade-Ideas: CytRx Corporation (CYTR) Is Today's "Dead Cat Bounce" Stock
at The Street - Mon Feb 03, 8:47AM CST
Trade-Ideas LLC identified CytRx Corporation (CYTR) as a "dead cat bounce" (down big yesterday but up big today) candidate
What to Watch at Merck, CytRx, and Mylan This Morning
Leo Sun, The Motley Fool - Motley Fool - Mon Feb 03, 8:16AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Good morning, fellow Foolish investors! Let's take a closer...
CytRx to Present at the 16th Annual BIO CEO & Investor Conference on February 10, 2014, in New York City
Business Wire - Mon Feb 03, 5:30AM CST
CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that President and CEO Steven A. Kriegsman and Vice President of Business Development David Haen will present at the 16th Annual BIO CEO & Investor Conference on Monday, February 10, 2014, at 2:30 p.m. Eastern time (11:30 a.m. Pacific time). The conference is being held February 10-11 at the Waldorf Astoria Hotel in New York City.
Sorrento Therapeutics Welcomes Daniel Levitt as a Director to its Board
PR Newswire - Mon Feb 03, 5:00AM CST
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento) a late-stage clinical oncology company developing new treatments for cancer and associated pain, today announced the addition of Clinical Oncologist Daniel Levitt, M.D., Ph.D., as a member to its Board of Directors. He currently serves as Executive Vice President and Chief Medical Officer of CytRx Corporation.
